EVO vs. GPCR, CPRX, HRMY, AGIO, GLPG, SDGR, SUPN, NAMS, SNDX, and EWTX
Should you be buying Evotec stock or one of its competitors? The main competitors of Evotec include Structure Therapeutics (GPCR), Catalyst Pharmaceuticals (CPRX), Harmony Biosciences (HRMY), Agios Pharmaceuticals (AGIO), Galapagos (GLPG), Schrödinger (SDGR), Supernus Pharmaceuticals (SUPN), NewAmsterdam Pharma (NAMS), Syndax Pharmaceuticals (SNDX), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical preparations" industry.
Evotec (NASDAQ:EVO) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Evotec currently has a consensus target price of $11.00, suggesting a potential upside of 105.61%. Structure Therapeutics has a consensus target price of $85.71, suggesting a potential upside of 138.16%. Given Structure Therapeutics' higher probable upside, analysts clearly believe Structure Therapeutics is more favorable than Evotec.
5.8% of Evotec shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Structure Therapeutics had 7 more articles in the media than Evotec. MarketBeat recorded 11 mentions for Structure Therapeutics and 4 mentions for Evotec. Structure Therapeutics' average media sentiment score of 0.95 beat Evotec's score of 0.94 indicating that Structure Therapeutics is being referred to more favorably in the news media.
Evotec's return on equity of 0.00% beat Structure Therapeutics' return on equity.
Structure Therapeutics has lower revenue, but higher earnings than Evotec.
Structure Therapeutics received 12 more outperform votes than Evotec when rated by MarketBeat users. Likewise, 78.95% of users gave Structure Therapeutics an outperform vote while only 75.00% of users gave Evotec an outperform vote.
Summary
Structure Therapeutics beats Evotec on 8 of the 11 factors compared between the two stocks.
Get Evotec News Delivered to You Automatically
Sign up to receive the latest news and ratings for EVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding EVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
